Thursday, July 17, 2025 11:33:21 AM
LOL, no regulatory agency will even consider this for anything outside GBM. Forget about approval. You have to run proper trials.
By the way, Specials revenue over the last few years will tell you everything you need to know about how much traction they have gotten, LOL! There is limited sample size of Specials data even for GBM. Forget about other indications! No doctors will stick their neck out to recommend a $200k therapy for other indications without proper clinical trial data and evidence. In fact, 99% of the oncology doctors outside GBM don’t even know NWBO and DCVAX!
They can’t even get approval for GBM indication 19 months post submission while the share price has been trading in .20s and minions pumping multiple indications outside GBM. LP just diluted at .22. Let that sink in!
As soon as the financiers dump their 17M+ shares to bag holders, we will be back to teens quickly. But hey it will be the market makers and manipulators then!
By the way, Specials revenue over the last few years will tell you everything you need to know about how much traction they have gotten, LOL! There is limited sample size of Specials data even for GBM. Forget about other indications! No doctors will stick their neck out to recommend a $200k therapy for other indications without proper clinical trial data and evidence. In fact, 99% of the oncology doctors outside GBM don’t even know NWBO and DCVAX!
They can’t even get approval for GBM indication 19 months post submission while the share price has been trading in .20s and minions pumping multiple indications outside GBM. LP just diluted at .22. Let that sink in!
As soon as the financiers dump their 17M+ shares to bag holders, we will be back to teens quickly. But hey it will be the market makers and manipulators then!
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
